Chaitali Nangia, MD, Patty and George Hoag Cancer Center

Looking Toward the Future Management of Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 16th 2022

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Novel Therapy for NSCLC With ALK Rearrangements

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 9th 2022

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Novel Therapy for NSCLC With KRAS G12C Mutation

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jonathan Riess, MD;Jessica Donington, MD, MSCR;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 9th 2022

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Heather Wakelee, MD;Alexander Spira, MD, PhD, FACP

August 2nd 2022

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jonathan Riess, MD;Jessica Donington, MD, MSCR;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 2nd 2022

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC With EGFR Mutations

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

July 26th 2022

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

July 26th 2022

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 19th 2022

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 19th 2022

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 12th 2022

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

July 5th 2022

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

July 5th 2022

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

Real-World Data and Barriers to Use of Molecular Testing in NSCLC

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

June 28th 2022

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Heather A. Wakelee, MD, FASCO

June 28th 2022

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Immunotherapy for NSCLC: Clinical Pearls

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 25th 2021

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

Blood-Based Biomarkers in NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 25th 2021

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Perioperative Approaches to NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

August 25th 2021

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Biomarkers for Immunotherapy in Resectable NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 18th 2021

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 18th 2021

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Neal Edward Ready, MD, PhD, Duke Medical Center;Sandip P. Patel, MD, University of California San Diego

August 11th 2021

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 11th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

CRT and I-O for Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 4th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Appropriateness for Durvalumab in Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 4th 2021

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

Risks of Pneumonitis in Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 28th 2021

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

Durvalumab for Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 28th 2021

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.